Swedbank AB Sells 21,422 Shares of DexCom, Inc. $DXCM

Swedbank AB lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 9.6% in the fourth quarter, Holdings Channel reports. The firm owned 202,556 shares of the medical device company’s stock after selling 21,422 shares during the period. Swedbank AB’s holdings in DexCom were worth $13,444,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the stock. Trust Co. of Vermont raised its stake in DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after acquiring an additional 145 shares in the last quarter. CVA Family Office LLC raised its stake in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares in the last quarter. IFP Advisors Inc raised its stake in DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after acquiring an additional 178 shares in the last quarter. Personal CFO Solutions LLC raised its stake in DexCom by 5.0% during the third quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after acquiring an additional 185 shares in the last quarter. Finally, Integrated Wealth Concepts LLC raised its stake in DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Mizuho set a $75.00 price objective on DexCom in a research note on Friday, May 1st. Benchmark assumed coverage on DexCom in a research note on Monday, May 11th. They set a “buy” rating and a $77.00 price objective for the company. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a research note on Tuesday, March 24th. Finally, Wells Fargo & Company dropped their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $82.21.

Insider Activity at DexCom

In related news, Director Bridgette P. Heller sold 1,012 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the transaction, the director owned 25,007 shares in the company, valued at $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the transaction, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. This represents a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,871 shares of company stock worth $2,306,638 over the last 90 days. Insiders own 0.28% of the company’s stock.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $72.01 on Wednesday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The firm has a market cap of $27.79 billion, a PE ratio of 30.77, a price-to-earnings-growth ratio of 1.19 and a beta of 1.40. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The business has a fifty day moving average of $63.87 and a 200-day moving average of $66.18.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period last year, the company posted $0.32 earnings per share. The firm’s quarterly revenue was up 15.0% compared to the same quarter last year. On average, equities research analysts predict that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.